Five Arrows

Five Arrows is actively evaluating pharmaceutical and life science consulting firms as acquisition targets

Leadership read: The acquisition hunt Five Arrows is running in pharma and life science consulting reflects a structural bet on complexity as a durable revenue model. Drug R&D has become materially harder to navigate, longer trial timelines, tighter regulatory scrutiny, and AI-driven data requirements that most sponsors lack the internal capability to absorb, and consulting firms positioned at that intersection are generating recurring, high-utilisation revenue that PE buyers find defensible. Acquiring into this space commits a buyer to integrating subject-matter-dense businesses where the asset is the team, not the balance sheet, which creates a very different post-close operating challenge than a product or distribution platform. This is one of twelve ma_activity signals we have tracked in the last 90 days, though the related set is broadly dispersed across sectors. The more instructive cluster is the pharma-specific thread in the source: Blackstone and Audax running parallel evaluation processes, and Eir Partners backing QuartzBio on the data-analytics side. That trio of moves, all surfacing within the same reporting period, points to concentrated PE attention on life sciences services as an asset class rather than isolated opportunism. Across firms building platforms in this corridor, the pattern consistently creates demand for commercial leadership with services-business fluency, specifically operators who can manage client concentration risk, retain billable talent through integration, and build cross-sell architecture across regulatory, clinical, and data capabilities. Revenue-operations and talent-retention functions carry disproportionate weight in consulting roll-ups where intellectual capital is the core asset.

curated · 2026-05-15 · context →